Last reviewed · How we verify
Shuxuening Injection
Shuxuening Injection is a traditional Chinese medicine compound that has been shown to have anti-inflammatory and immunomodulatory effects.
Shuxuening Injection is a traditional Chinese medicine compound that has been shown to have anti-inflammatory and immunomodulatory effects. Used for Treatment of severe COVID-19.
At a glance
| Generic name | Shuxuening Injection |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | Traditional Chinese medicine compound |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of Shuxuening Injection is not fully understood, but it is believed to work by modulating the immune system and reducing inflammation. This is thought to be achieved through the interaction of its various components with different molecular targets, although the specific pathways involved are not yet well characterized.
Approved indications
- Treatment of severe COVID-19
Common side effects
- Injection site reaction
Key clinical trials
- Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) (PHASE3)
- Shuxuening Injection for the Prevention of CVS in Patients With aSAH(SXN-CVS) (PHASE2, PHASE3)
- Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke (PHASE4)
- Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase (PHASE2)
- A Registry Study of Shuxuening Injection Used in Hospitals in China
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shuxuening Injection CI brief — competitive landscape report
- Shuxuening Injection updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI